UroGen Pharma (FRA:UR8) Cyclically Adjusted FCF per Share: €-2.70 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UR8 UroGen Pharma Ltd FRA:UR8
60 GF Score
Price €34.54
GF Value €18.68
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma Cyclically Adjusted FCF per Share?

UroGen Pharma FRA:UR8 -1.34% 60 Cyclically Adjusted FCF per Share is €-2.70 as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 60/100 and a GF Value™ of €18.68 (Significantly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

UroGen Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.782. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.70 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-31), UroGen Pharma's current stock price is €34.54. UroGen Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-2.70. UroGen Pharma's Cyclically Adjusted Price-to-FCF of today is .


UroGen Pharma  (FRA:UR8) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


UroGen Pharma Cyclically Adjusted FCF per Share Related Terms


UroGen Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Cyclically Adjusted FCF per Share Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2.69

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.69 -2.70

FRA:UR8 vs PVLA, AUPH, RAPP: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, UroGen Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:UR8
60GF Score
UroGen Pharma Ltd FRA:UR8
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, UroGen Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.782/330.2130*330.2130
=-0.782

Current CPI (Mar. 2026) = 330.2130.

UroGen Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.251 241.018 -0.344
201609 -0.272 241.428 -0.372
201612 1.047 241.432 1.432
201703 -0.241 243.801 -0.326
201706 -0.337 244.955 -0.454
201709 0.166 246.819 0.222
201712 -0.364 246.524 -0.488
201803 -0.515 249.554 -0.681
201806 -0.449 251.989 -0.588
201809 -0.512 252.439 -0.670
201812 -0.572 251.233 -0.752
201903 -0.823 254.202 -1.069
201906 -0.620 256.143 -0.799
201909 -0.546 256.759 -0.702
201912 -1.123 256.974 -1.443
202003 -1.528 258.115 -1.955
202006 -0.989 257.797 -1.267
202009 -0.991 260.280 -1.257
202012 -0.795 260.474 -1.008
202103 -1.046 264.877 -1.304
202106 -0.707 271.696 -0.859
202109 -0.709 274.310 -0.853
202112 -0.800 278.802 -0.948
202203 -0.964 287.504 -1.107
202206 -1.011 296.311 -1.127
202209 -0.787 296.808 -0.876
202212 -0.890 296.797 -0.990
202303 -1.036 301.836 -1.133
202306 -0.798 305.109 -0.864
202309 -0.505 307.789 -0.542
202312 -0.330 306.746 -0.355
202403 -0.788 312.332 -0.833
202406 -0.545 314.175 -0.573
202409 -0.533 315.301 -0.558
202412 -0.276 315.605 -0.289
202503 -0.821 319.799 -0.848
202506 -0.726 322.561 -0.743
202509 -0.751 324.800 -0.764
202512 -0.665 324.054 -0.678
202603 -0.782 330.213 -0.782

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.70 mean?
UroGen Pharma (FRA:UR8) has a Cyclically Adjusted FCF per Share of €-2.70 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's Cyclically Adjusted FCF per Share too high?
UroGen Pharma's current Cyclically Adjusted FCF per Share is €-2.70. Overall, UroGen Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Cyclically Adjusted FCF per Share compare to PVLA and AUPH?
UroGen Pharma's Cyclically Adjusted FCF per Share of €-2.70 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Cyclically Adjusted FCF per Share is €-2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.68, compared to a current price of €34.54 — trading 84.9% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-2.70. UroGen Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Cyclically Adjusted FCF per Share is €-2.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €34.54 is trading 84.9% above its estimated GF Value™ of €18.68. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • Cyclically Adjusted FCF per Share: €-2.70
  • GF Value™: €18.68 vs. price of €34.54 (84.9% above fair value)
  • GF Score™: 60/100 with 10 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
60GF Score

Get the complete analysis for FRA:UR8

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.54
Price
€18.68
GF Value